David A Siler

Title: David A. Siler: Innovator in Pharmaceutical Chemistry

Introduction

David A. Siler is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of MCL-1 inhibitors. His work focuses on the creation of salts and polymorphs that enhance the efficacy of these compounds.

Latest Patents

David A. Siler holds a patent for "Salts and polymorphs of certain MCL-1 inhibitors." This patent relates to the salts and crystalline forms of specific 3',4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene] derivatives. The disclosure also covers pharmaceutical formulations and therapeutic uses of these compounds, as well as methods for preparing such salts and crystalline forms.

Career Highlights

David A. Siler is currently employed at Gilead Sciences, Inc., where he continues to advance his research in pharmaceutical innovations. His work has contributed to the development of new therapeutic options for various diseases.

Collaborations

Throughout his career, David has collaborated with esteemed colleagues, including Christopher S. Regens and John Enquist, Jr. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

David A. Siler is a prominent figure in the field of pharmaceutical chemistry, with a focus on MCL-1 inhibitors. His innovative work and collaborations have the potential to lead to significant advancements in therapeutic applications.